Skip to main content

Advertisement

SpringerLink
Log in

A cancer trial scandal and its regulatory backlash

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Regulatory fallout from a scandal surrounding the fabrication of data used to support a molecular test in a Duke University cancer trial is exacting an unjustifiable toll not only on health economics but also on patient lives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hart, P.K. Houston docs found leak in Holy Grail of cancer treatment. Houston Chronicle http://www.chron.com/news/kilday-hart/article/Hart-Houston-docs-found-leak-in-Holy-Grail-of-3341794.php (18 February 2012).

    Google Scholar 

  2. Institute of Medicine. Evolution of translational omics: lessons learned and the path forward. http://www.iom.edu/Reports/2012/Evolution-of-Translational-Omics/Report-Brief.aspx (23 March 2012).

  3. US Food and Drug Administration. Device advice: investigational device exemption (IDE). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance /HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/default.htm (updated 23 December 2013).

  4. Kim, E.S. et al. Cancer Discov. 1, 44–53 (2011).

    Article  CAS  Google Scholar 

  5. Beckloff Associates, Inc. The regulatory paradox of laboratory developed tests. http://cardinalhealth.com/beckloff/documents/pdf/TheRegulatoryParadoxofLaboratoryDevelopedTests.pdf (accessed 12 December 2013).

  6. Non-Small Cell Lung Cancer Collaborative Group. Br. Med. J. 311, 899–909 (1995).

  7. National Cancer Institute. Non-small cell lung cancer treatment. http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/page11#Section_48414 (updated 30 May 2013).

  8. Laack, E. et al. J. Clin. Oncol. 22, 2348–2356 (2004).

    Article  CAS  Google Scholar 

  9. Monnerat, C. & Le Chevalier, T. Ann. Oncol. 17 (suppl. 5), v86–v90 (2006).

    Article  Google Scholar 

  10. Spigel, D.R. et al. J. Thorac. Oncol. 5, 841–845 (2010).

    Article  Google Scholar 

  11. D'Addario, G. et al. J. Clin. Oncol. 23, 2926–2936 (2005).

    Article  CAS  Google Scholar 

  12. Rajeswaran, A., Trojan, A., Burnand, B. & Giannelli, M. Lung Cancer 59, 1–11 (2008).

    Article  Google Scholar 

  13. Pujol, J.L., Barlesi, F. & Daurès, J.P. Lung Cancer 51, 335–345 (2006).

    Article  Google Scholar 

  14. Verma, S. et al. N. Engl. J. Med. 367, 1783–1791 (2012).

    Article  CAS  Google Scholar 

  15. US Food & Drug Administration. FDA approves new treatment for late-stage breast cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm (22 February 2013).

  16. Burris, H.A. III et al. J. Clin. Oncol. 29, 398–405 (2011).

    Article  CAS  Google Scholar 

  17. F. Hoffman-La Roche Ltd. Roche provides update on FDA application for T-DM1. http://www.roche.com/media/media_releases/med-cor-2010-08-27.htm (27 August 2010).

  18. Stewart, D.J., Whitney, S.N. & Kurzrock, R. J. Clin. Oncol. 28, 2925–2935 (2010).

    Article  Google Scholar 

  19. Westin, J.R. & Kurzrock, R. Mol. Cancer Ther. 11, 2549–2555 (2012).

    Article  CAS  Google Scholar 

  20. Kantarjian, H. et al. N. Engl. J. Med. 362, 2260–2270 (2010).

    Article  CAS  Google Scholar 

  21. Behazin, N.S. Gastrointestinal stromal tumors. Medscape http://emedicine.medscape.com/article/179669-overview (updated 11 March 2013).

  22. Stewart, D.J. & Kurzrock, R. J. Clin. Oncol. 27, 328–333 (2009).

    Article  Google Scholar 

  23. Schulman, K.A. J. Investig. Med. 58, 31–32 (2010).

    Google Scholar 

  24. Most clinical trials done abroad. Wall Street Journal http://online.wsj.com/news/articles/SB123499424805316443 (18 February 2009).

  25. Janku, F. et al. Clin. Cancer Res. 18, 6356–6363 (2012).

    Article  CAS  Google Scholar 

  26. Tsimberidou, A.M. et al. Clin. Cancer Res. 18, 6373–6383 (2012).

    Article  CAS  Google Scholar 

  27. Stewart, D.J. & Kurzrock, R. BMC Cancer 13, 193 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Razelle Kurzrock is at the University of California, San Diego Moores Cancer Center, San Diego, California, USA,

    Razelle Kurzrock

  2. Hagop Kantarjian is at the Department of Leukemia, D Anderson Cancer Center, Houston, Texas, USA,

    Hagop Kantarjian

  3. David J. Stewart is at the Division of Medical Oncology, The University of Ottawa, Ottawa, Canada.,

    David J Stewart

Authors
  1. Razelle Kurzrock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hagop Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Razelle Kurzrock.

Ethics declarations

Competing interests

R.K. received a Merck Honorarium ($3,500). D.J.S. has been a consultant for various firms, including the Frankel Group, Aligh2Action, Amgen, Roche Canada, Boehringer Ingelheim Canada and Guidepoint Global; has been a speaker at events sponsored by Pfizer Canada, AstraZeneca Taiwan and Ventana; and has been supported by grants to his institution from AstraZeneca, Roche Canada and Pfizer. None of foregoing for D.J.S. is related to the present work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurzrock, R., Kantarjian, H. & Stewart, D. A cancer trial scandal and its regulatory backlash. Nat Biotechnol 32, 27–31 (2014). https://doi.org/10.1038/nbt.2792

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2792

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation